Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Long-Term Laxatives for End-Stage Renal Disease

Primary Recommendation: Polyethylene Glycol (PEG)

  • The American College of Gastroenterology recommends polyethylene glycol (PEG) as the first-line agent for patients with end-stage renal disease (ESRD) requiring long-term laxative therapy, due to its safety in renal impairment and maintenance of electrolyte balance 1, 2, 3
  • PEG is the optimal choice for ESRD patients because it does not accumulate in renal failure and maintains electrolyte balance 1, 2, 3
  • The initial dose of PEG is 17 g daily, which can be titrated up to 41.1 g/day based on response 4
  • PEG demonstrates minimal adverse effects, with common side effects limited to mild bloating and abdominal discomfort that typically resolve with dose adjustment 4
  • The monthly cost of PEG is approximately $10-45, making it a highly cost-effective option 4

Second-Line Option: Lactulose

  • Lactulose is an acceptable alternative to PEG, with additional renoprotective benefits demonstrated in chronic kidney disease (CKD) populations 1, 2
  • The initial dose of lactulose is 15 g daily, which can be titrated based on response 4
  • Lactulose is not absorbed by the small bowel, making it safe in ESRD patients 1, 2
  • Lactulose has a 2-3 day latency before onset of effect 5
  • Critical side effects of lactulose include sweet taste, nausea, and abdominal distention, which may limit tolerability, particularly at higher doses 1, 5

Stimulant Laxatives: Use with Caution

  • Stimulant laxatives, such as senna and bisacodyl, can be used as rescue therapy or for short-term use, but should be reserved for patients who do not respond to PEG or lactulose 1, 2, 4
  • The initial dose of senna is 8.6-17.2 mg daily, with a maximum dose of 4 tablets twice daily 4
  • The initial dose of bisacodyl is 5 mg daily, with a maximum dose of 10 mg daily 4
  • Long-term safety and efficacy data are lacking for chronic use of stimulant laxatives 4
  • Side effects of stimulant laxatives include cramping and abdominal discomfort that may limit adherence 4

Strictly Contraindicated Agents in ESRD

  • Magnesium-containing laxatives, such as magnesium oxide and magnesium salts, are absolutely contraindicated in ESRD patients due to impaired renal clearance leading to potentially fatal hypermagnesemia 1, 2, 3
  • Sodium phosphate enemas are contraindicated in ESRD patients, as they can cause severe electrolyte disturbances, including hyperphosphatemia and acute kidney injury 6

Newer Agents: Consider for Refractory Cases

  • Lubiprostone, a chloride channel activator, can be considered for refractory cases at a dose of 24 μg twice daily 4
  • Lubiprostone demonstrates renoprotective effects in CKD populations, but may cause diarrhea leading to discontinuation in some patients 4
  • The monthly cost of lubiprostone is approximately $374 4
  • Linaclotide and plecanatide can be considered for refractory cases at doses of 72-145 μg daily and 3 mg daily, respectively 4
  • The monthly cost of linaclotide and plecanatide is approximately $523-526 4

Agents to Avoid

  • Bulk-forming laxatives, such as psyllium and methylcellulose, are not recommended in ESRD patients due to the requirement for high fluid intake and diminishing efficacy over time 1, 2, 5
  • Stool softeners, such as docusate, have inadequate evidence for efficacy and should not be relied upon as primary therapy 5

Clinical Algorithm for ESRD Patients

  • The American College of Gastroenterology recommends a clinical algorithm for ESRD patients, starting with PEG 17 g daily, followed by lactulose 15 g daily if intolerant to PEG, and adding short-term stimulant laxative (senna or bisacodyl) for rescue if inadequate response 1, 2, 4
  • If refractory, consider lubiprostone, linaclotide, or plecanatide 4

Critical Monitoring Parameters

  • Electrolytes, including calcium, phosphate, and magnesium, should be monitored regularly, especially if any osmotic agent is used 1
  • Volume status should be assessed for dehydration or fluid overload, particularly in dialysis patients 3
  • Bowel movement frequency should be targeted at 3-5 bowel movements per week minimum 4
  • Medication reconciliation should be performed to review for constipating medications that may require adjustment 4

Common Pitfalls to Avoid

  • Magnesium-containing products should never be prescribed to ESRD patients due to the risk of potentially fatal hypermagnesemia 1, 2, 3
  • Sodium phosphate enemas should not be used for bowel preparation or constipation management in ESRD patients due to the risk of severe electrolyte disturbances 6
  • Escalation to enemas should be avoided when oral laxatives fail without first ruling out bowel obstruction, as enemas are contraindicated in obstruction and can cause perforation 7